| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NA | Ceritinib | Zykadia | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2014 | In Use | |||
| J9057 | Copanlisib | Aliqopa | 1mg | Chemotherapy | Enzyme Inhibitor | PI3K | No | 2017 | In Use | |||
| NA | Dasatinib | Sprycel | 50 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
| Q5136 | Denosumab-bbdz | Jubbonti/Wyost | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2024 | Sep 11, 2024 | In Use | ||
| J0893 | Decitabine (Sun Pharma) | Decitabine | 1mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2014 | Dec 21, 2022 | In Use | ||
| Fruquintinib | Fruzaqla | 1mg, 5mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2023 | In Use | ||||
| J8612 | Methotrexate (xatmep) | Xatmep | 2.5mg | Chemotherapy | Antimetabolite | Folic Acid Analog | Yes | 2017 | Jun 10, 2024 | In Use | ||
| J9299 | Nivolumab | Opdivo | 1 mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2014 | Jan 1, 2016 | In Use | ||
| NA | Duvelisib | Copiktra | 15mg, 25mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2018 | In Use | |||
| J9190 | Fluorouracil | Adrucil | 500 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1962 | Jan 1, 1984 | In Use | ||
| NA | Fluprednisolone Valerate | Alphadrol | 1.5 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | In Use | ||||
| S0174 | Dolasetron Mesylate | Anzemet | 50 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Yes | 1997 | Jan 1, 2002 | In Use | ||
| J9000 | Doxorubicin | Adriamycin | 10 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1989 | Jan 1, 1984 | In Use | ||
| J9176 | Elotuzumab | Empliciti | 1 mg | Immunotherapy | Monoclonal Antibody | SLAMF7 | No | 2015 | Jan 1, 2017 | In Use | ||
| J1626 | Granisetron Hydrochloride | Granisol [DSC], Sancuso, Sustol, Kytril | 100 mcg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 1993 | Jan 1, 2009 | In Use | ||
| NA | Sunitinib malate | Sutent | 50 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR,KIT, RET, CSF | Yes | 2006 | In Use | |||
| C9480 | Trabectedin | Yondelis | 0.1 mg | Chemotherapy | Alkylating Agent | Natural Product | No | 2015 | Jul 1, 2016 | In Use | ||
| J2783 | Rasburicase | Elitek, Fasturtec | 0.5 mg | Ancillary Therapy | Metabolic Agent | Enzyme | No | 2002 | Jan 1, 2004 | In Use | ||
| J9274 | Tebentafusp-tebn | Kimmtrak | 1mcg | Immunotherapy | T Cell Receptor (TCR) | HLA-A*02:01 | No | 2022 | Sep 27, 2022 | In Use | ||
| NA | Crizotinib | Xalkori | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2011 | In Use | |||
| J1726 | Hydroxyprogesterone Caproate | Makena | 10 mg | Hormonal Therapy | Progestin | No | 2011 | Jan 1, 2018 | In Use | |||
| J3590 | Immunotherapy - non specific | Unclassified biologics | NA | Immunotherapy | No | Jan 1, 2003 | In Use | |||||
| J9356 | Trastuzumab and Hyaluronidase-oysk | Herceptin hylecta | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2019 | Jul 1, 2019 | In Use | ||
| J9355 | Trastuzumab | Herceptin | 10 mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 1998 | Jan 1, 2000 | In Use | ||
| J9214 | Interferon Alfa-2b | Intron A | 1 million units | Immunotherapy | Cytokine | Interferon | No | 1986 | Jan 1, 1993 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home